Swiss pharmaceuticals giant Novartis said Monday it would sell its blood transfusion diagnostics unit to the Spanish firm Grifols for $1.68 billion (1.25 billion euros), with analysts saying more divestments could lay in ...
Nov 11, 2013
0
0
Swiss pharmaceuticals giant Novartis said Wednesday it aimed to slash more than 440 jobs in Britain, blaming industry-wide difficulties.
Nov 6, 2013
0
0
Swiss pharmaceutical giant Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan, even though it said negative currency trends contributed to ...
Oct 22, 2013
0
0
LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination ...
Oct 20, 2013
0
0
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.
Oct 1, 2013
0
0
Japanese authorities are preparing to raid the local arm of Swiss pharmaceutical giant Novartis over data fabrication claims, reports said Friday.
Sep 27, 2013
0
0
(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug safety alert issued ...
Aug 31, 2013
0
0
A new strategy that cripples the ability of the dengue virus to escape the host immune system has been discovered by A*STAR's Singapore Immunology Network (SIgN). This breakthrough strategy opens a door of hope to what may ...
Aug 13, 2013
0
0
A Japanese university Wednesday said it would retract a study that touted the effectiveness of a blood pressure drug made by Swiss pharmaceutical giant Novartis because it was based on fabricated data.
Jul 31, 2013
0
0
(AP)—Swiss pharmaceutical company Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter.
Jul 17, 2013
0
0
